Try our beta test site
2 studies found for:    Lymphoma OR CLL | cc-223
Show Display Options
Rank Status Study
1 Recruiting Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma
Condition: Lymphoma, Large B-Cell, Diffuse
Interventions: Drug: CC-122;   Drug: CC-223;   Drug: Rituximab;   Drug: CC-292
2 Active, not recruiting Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Conditions: Multiple Myeloma;   Diffuse Large B-Cell Lymphoma;   Glioblastoma Multiforme;   Hepatocellular Carcinoma;   Non-Small Cell Lung Cancer;   Neuroendocrine Tumors of Non-Pancreatic Origin;   Hormone Receptor-Positive Breast Cancer
Intervention: Drug: CC-223

Study has passed its completion date and status has not been verified in more than two years.